Lead Product(s): Lidocaine Hydrochloride
Therapeutic Area: Neurology
Highest Development Status: Approved Product Type: Small molecule
Deal Size: $440 million Upfront Cash: $330.0 million
Deal Type: Acquisition January 31, 2020
The acquisition strengthens Sandozâ€™s presence in the hospital channel by complementing the broad Sandoz portfolio and pipeline of hospital generic and biosimilar products in Japan.